Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced that it will release its third quarter 2024 financial results after the close of trading on Wednesday, October 30, 2024. The company management will host a conference call to discuss the financial results, starting at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
Investors and interested parties can access a live and archived webcast of the event on the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/. This announcement provides an opportunity for stakeholders to gain insights into the company's financial performance and future outlook.
Positive
- None.
Negative
- None.
News Market Reaction – LUNG
In the trading session that priced this news, LUNG declined 5.74%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
